Anthony Mancini, Chief Global Commercialization Officer, on September 10, 2026, sold 15,448 shares in Revolution Medicines (RVMD) for $3,153,807. Following the Form 4 filing with the SEC, Mancini has control over a total of 43,890 common shares of the company, with 43,890 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1628171/000212450926000004/xslF345X05/ownership.xml
Kevin K Gordon, Director, on September 10, 2026, sold 11,500 shares in Progyny (PGNY) for $321,358. Following the Form 4 filing with the SEC, Gordon has control over a total of 6,792 common shares of the company, with 6,792 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1551306/000155130626000152/xslF345X05/wk-form4_1789422827.xml
Thomas J Smach, Director, on September 10, 2026, executed a purchase for 4,000 shares in Crocs (CROX) for $437,530. Following the Form 4 filing with the SEC, Smach has control over a total of 211,728 common shares of the company, with 93,249 shares held directly and 118,479 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1334036/000119410626000012/xslF345X05/wk-form4_1789420882.xml
Michael P Donaldson, Executive Vice President & Chief Legal Officer, on September 11, 2026, sold 7,336 shares in Eog Resources (EOG) for $1,085,728. Following the Form 4 filing with the SEC, Donaldson has control over a total of 130,558 common shares of the company, with 100,558 shares held directly and 30,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/821189/000082118926000174/xslF345X05/form4.xml